Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance—India, 2018–2020
Tamilzhalagan S, Justin E, Selvaraj A, Venkateswaran K, Sivakumar A, Chittibabu S, McLaughlin H, Moonan P, Smith J, Suba S, Narayanan M, Ho C, Kumar N, Tripathy S, Shanmugam S, Hall-Eidson P, Ranganathan U. Phenotypic and genotypic characterization of Mycobacterium tuberculosis pyrazinamide resistance—India, 2018–2020. Frontiers In Microbiology 2025, 15: 1515627. PMID: 39845030, PMCID: PMC11750862, DOI: 10.3389/fmicb.2024.1515627.Peer-Reviewed Original ResearchPZA resistancePyrazinamide resistanceMultidrug resistanceDuration of tuberculosis treatmentWhole-genome sequencingPrevalence of mutationsSecond-line drugsPZA-resistant isolatesResistance-conferring mutationsGenome sequenceTB burden countriesLineage 2Genotypic characterizationResistance markersNovel mutationsPhenotypic resistanceMutational diversityDiagnostic accuracyTuberculosis treatmentAntituberculosis drugsCo-resistanceBurden countriesPyrazinamideMutationsTB prevention
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply